Cas:361202-16-6 9H-pyrido[3,4-b]indole-6-carbonitrile manufacturer & supplier

Chemical Name:9H-pyrido[3,4-b]indole-6-carbonitrile

CAS.NO:361202-16-6

Synonyms:9H-pyrido[3,4-b]indole-6-carbonitrile

Molecular Formula:C₁₂H₇N₃

Molecular Weight:193.20400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.47000

Exact Mass:193.06400

LogP:2.58778

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 9H-pyrido[3,4-b]indole-6-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9H-pyrido[3,4-b]indole-6-carbonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9H-pyrido[3,4-b]indole-6-carbonitrile Use and application,9H-pyrido[3,4-b]indole-6-carbonitrile technical grade,usp/ep/jp grade.

Related News: The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. 9H-pyrido[3,4-b]indole-6-carbonitrile manufacturer ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. 9H-pyrido[3,4-b]indole-6-carbonitrile supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. 9H-pyrido[3,4-b]indole-6-carbonitrile vendor The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 9H-pyrido[3,4-b]indole-6-carbonitrile factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.